Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome

Lauren Skudalski; Neda Shahriari; Kristin Torre; Sueheidi Santiago; Lorin Bibb; Vijay Kodomudi; Jane M Grant-Kels; Jun Lu

doi:10.1016/j.jaad.2021.12.067

Emerging therapeutics in the management of connective tissue disease. Part I. Lupus erythematosus and Sjögren syndrome

J Am Acad Dermatol. 2022 Jul;87(1):1-18. doi: 10.1016/j.jaad.2021.12.067. Epub 2022 Feb 22.

Authors

Lauren Skudalski¹, Neda Shahriari², Kristin Torre³, Sueheidi Santiago³, Lorin Bibb³, Vijay Kodomudi³, Jane M Grant-Kels³, Jun Lu⁴

Affiliations

¹ Geisinger Commonwealth School of Medicine, Scranton, Pennsylvania.
² Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
³ Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut.
⁴ Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut. Electronic address: [email protected].

PMID: 35202775
DOI: 10.1016/j.jaad.2021.12.067

Abstract

The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The first article in this continuing medical education series discusses new and emerging therapeutics for lupus erythematosus and Sjögren syndrome that target cells, intracellular signaling pathways, and cytokines.

Keywords: Sjögren; clinical trials; current management; cutaneous lupus erythematosus; new treatments; systemic lupus erythematosus.

Publication types

Review

MeSH terms

Biological Products*
Connective Tissue Diseases* / therapy
Humans
Lupus Erythematosus, Systemic* / complications
Lupus Erythematosus, Systemic* / drug therapy
Sjogren's Syndrome* / complications
Sjogren's Syndrome* / drug therapy

Substances

Biological Products